Comparative Pharmacology
Head-to-head clinical analysis: DEXEDRINE versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXEDRINE versus EVEKEO ODT.
DEXEDRINE vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant